Communiqués 3SBio Inc.

Actions

1530

KYG8875G1029

Produits pharmaceutiques

Temps Différé Hong Kong S.E. 05:52:30 23/09/2026			Varia. 5j.	Varia. 1 janv.
17,09 ^HKD	+1,91%		+8,93%	-29,36%

21/08	Le bénéfice attribuable de 3SBio chute de 16 % au S1 2024	MT
20/08	3SBio Inc. publie ses résultats pour le semestre clos le 30 juin 2026	CI

Communiqués

21/08	Sunshine Guojian Releases 2026 Interim Report	PR
01/09/25	3SBio : 2025 Interim Results Presentation	PU
30/04/25	3SBio : 2024 ESG Report	PU
25/03/25	3SBio Unveils 2024 Annual Results: Profit Surges 34.9% YoY, Innovation Pipeline Delivers Strong Value	PU
25/03/25	3SBio : 2024 Annual Results	PU
21/01/25	3SBio : 2025 43rd Annual J.P. Morgan Healthcare Conference Corporate Presentation	PU
30/09/24	3SBio : 2024 Interim Report	PU
22/08/24	3SBio Unveils 2024 Interim Results: Revenue Up 16% YoY, Autoimmune Pipeline Poised for a Promising Phase	PU
25/08/23	3SBio announces 2023 interim results, with revenue growing over 20% year on year and pipeline value constantly enhanced	PR
24/08/23	3SBio : 2023 Interim Results Presentation	PU
28/04/23	3SBio : 2022 ESG Report	PU
22/03/23	3SBio announces 2022 annual results, with revenue rising 7.5% year on year and normalized net profit attributable to parents jumping 25.2%	PR
24/08/22	3SBio : 2022 Interim Results Presentation	PU
24/06/22	3SBio : 1530.HK) _ Prospectus	PU
25/05/22	3SBio : 2021 ESG Report	PU
29/04/22	3SBio : 2021Annual Report	PU
30/03/22	3SBio : announces 2021 annual results, with net profit attributable to owns of the parents almost doubling under accelerated growth of diversified businesses	PU
29/03/22	3SBIO : 2021Annual Results	PU
21/12/21	3SBio : Documents on Display	PU
26/08/21	3SBio : announces 2021 interim results, with strong growth in core businesses and significant progress in clinical development	PU
30/03/21	3SBio : announces 2020 annual results, tapping integrated platform advantages for steady growth	PU
26/02/21	3SBio : PRELIMINARY RESULTS OF SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD. FOR THE YEAR ENDED 31 DECEMBER 2020	PU
14/12/20	3SBio : Sunshine Guojian Selects Verseau’s VSIG4-targeted Antibody as the Second Partnered Macrophage Checkpoint Modulator in Immuno-Oncology Collaboration	PU
23/11/20	3SBio Inc. : received milestone payment of USD 4 million upon commencement of phase III clinical program of SEL-212	PR
14/09/20	3SBio : Announces Acceptance of IND application for bevacizumab biosimilar in China	PU